Voyager Therapeutics (NASDAQ:VYGR) has been assigned a $13.00 price target by equities researchers at Morgan Stanley in a note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 5.52% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $28.00 price objective (up from $18.00) on shares of Voyager Therapeutics in a research note on Thursday. ValuEngine upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. BidaskClub raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 29th. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Voyager Therapeutics in a report on Monday, September 10th. Finally, Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $28.00.

NASDAQ VYGR opened at $12.32 on Thursday. Voyager Therapeutics has a 12 month low of $11.00 and a 12 month high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.15. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 73.99%. The firm had revenue of $2.09 million for the quarter, compared to the consensus estimate of $3.02 million. Analysts expect that Voyager Therapeutics will post -2.87 earnings per share for the current year.

In other news, Director Glenn Pierce acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were acquired at an average price of $18.44 per share, with a total value of $92,200.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James A. Geraghty acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 17th. The stock was purchased at an average cost of $18.31 per share, for a total transaction of $54,930.00. Following the acquisition, the director now owns 73,588 shares in the company, valued at $1,347,396.28. The disclosure for this purchase can be found here. Insiders have acquired 11,000 shares of company stock worth $205,300 over the last three months. 33.60% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY increased its holdings in shares of Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock worth $177,000 after acquiring an additional 3,157 shares during the period. MetLife Investment Advisors LLC increased its holdings in shares of Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock worth $208,000 after acquiring an additional 2,964 shares during the period. Thompson Davis & CO. Inc. increased its holdings in shares of Voyager Therapeutics by 187.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock worth $234,000 after acquiring an additional 7,800 shares during the period. Hershey Trust Co. acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter worth about $284,000. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Voyager Therapeutics by 27.4% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock worth $318,000 after acquiring an additional 3,500 shares during the period. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: How to calculate compound interest

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.